Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Hospitals and Health Care
ProsTIC Theranostics works in Hospitals and Health Care, out of Melbourne, VIC. A nonprofit, at petermac.org. It holds one address on record, all in Australia. It self-reports a headcount band of 2–10. It lists cancer among its specialties. The record links four similar brands, most of them in Fundraising.
Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells.
The ProsTIC program has three aims:
1. Accelerate clinical trial research: Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed.
2. Education and Leadership: Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology.
3. Discovery research: Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.
Email: prostic@petermac.org
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
One address on record, Australia only. Primary: 305 Grattan Street, Melbourne, VIC 3000.
12 tags on the brand's own list, among them cancer.
Four peer profiles on record: Australian Cancer Research Foundation and ANZUP Cancer Trials Group Limited.